Organo Corp.

As of March 31, 2026, Organo Corp. carries a market capitalization of 625.82B, placing it among publicly traded companies globally. Its enterprise value stands at 575.31B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Organo Corp.'s next confirmed earnings release is scheduled for November 4, 2026.

As of March 31, 2026, Organo Corp. has 229.91M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Organo Corp. maintains a current ratio of 2.71, meaning it holds 2.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, Organo Corp.'s stock has declined approximately 6.67% over the past 52 weeks. The 50-day moving average sits at 2,604.54, while the 200-day moving average is 2,991.98.

As of March 31, 2026, Organo Corp. holds 84.91B in cash and equivalents against 34.40B in total debt, resulting in a net debt position of 3.35B. Total book value stands at 142.96B, with working capital of 121.06B providing operational flexibility.

Organo Corp.'s most recent stock split took place on September 29, 2026 with a 1:5 split ratio.